The obsession with pounds lost can obscure what diabetes medicines are designed to do first: control glucose. Genentech’s investigational enicepatide, also known as CT-388, has supplied a useful reminder.
In a September 22, 2026 announcement, the company reported Phase 2 results for a once-weekly dual GLP-1/GIP receptor agonist in people with type 2 diabetes and overweight or obesity. At its highest studied dose, the compound produced large average A1C reductions alongside substantial weight loss.
These are company-reported results from September, not a fresh October 29 announcement.
The Diabetes Result Hiding Behind the Weight-Loss Race
Genentech reported an average A1C reduction of 2.65 percentage points at 48 weeks with enicepatide 24 mg, from a baseline A1C of 8.1 percent. In participants whose baseline A1C exceeded 8.5 percent, the company described a reduction of 4.13 percentage points.
It also said 90 percent of the highest-dose group reached an A1C of 6.5 percent or lower, while 62 percent reached a level below 5.7 percent.
Those thresholds are striking, but the release does not by itself establish how long such results persist or how they compare with a different drug in a head-to-head study.
The CT-388-104 trial, registered as NCT06628362, enrolled 447 adults with type 2 diabetes and overweight or obesity. It used a randomized, double-blind, placebo-controlled, multicenter design to evaluate once-weekly subcutaneous enicepatide.
That design provides stronger evidence than an uncontrolled observation, but it does not answer how enicepatide performs against established diabetes medicines.
The Weight-Loss Numbers Tell a Different Part of the Story
Weight outcomes added another dimension. The company reported 15.5 percent mean weight loss at 48 weeks in the 24 mg group, without a demonstrable plateau by that point.
The absence of a plateau in an observed trial window should not be read as a promise of unlimited weight loss. Longer follow-up may change the picture, and any interpretation must account for the statistical estimand, missing data and treatment discontinuation.
The important point is that the diabetes and weight results should be evaluated as related but distinct outcomes. A medicine may show meaningful glucose benefits without producing the most dramatic weight-loss percentage in the broader obesity pipeline.
The biggest diabetes-drug story is not always the biggest weight-loss percentage.
Two Receptors Do Not Automatically Mean Better Medicine
Enicepatide stimulates GLP-1 and GIP receptors, placing it in the same broad mechanistic family as other dual incretin approaches. Genentech describes the molecule as a biased agonist designed to activate both receptors while minimizing beta-arrestin recruitment, a signaling property that may influence receptor internalization and desensitization.
But molecules sharing receptor targets need not share identical dosing, tolerability, tissue exposure or long-term outcomes. Differences in formulation and pharmacology can affect how a compound performs.
The point of clinical development is to establish those distinctions in people, not to assume equivalence because a diagram shows the same two receptor names.
The trial’s diabetes population is particularly relevant. For some patients, reducing hyperglycemia and its complications may matter more than winning a headline comparison of kilograms.
At the same time, A1C is a surrogate marker. Definitive claims about cardiovascular protection, kidney outcomes or survival require their own evidence. The September release did not establish those downstream benefits.
The Safety Numbers Still Need the Harder Test
Genentech characterized safety and tolerability as consistent with the incretin class, with predominantly mild-to-moderate gastrointestinal adverse events and no new safety signals identified.
The company reported treatment discontinuation due to adverse events in 2.0 percent of participants across enicepatide groups, compared with 0.0 percent in the placebo arm.
That is an encouraging early signal, but a Phase 2 study cannot rule out uncommon harms or settle how patients will tolerate years of therapy. Detailed adverse-event tables, the full analysis plan and future independently scrutinized results remain important.
There is also a distinction between the reported week-48 findings and the trial’s formal endpoint hierarchy. Roche’s announcement describes week-48 A1C and weight outcomes as primary, whereas Genentech’s public trial overview lists week-36 outcomes as primary and week-48 outcomes as secondary. That discrepancy should be resolved against the protocol before drawing conclusions about the statistical hierarchy.
The company has a commercial incentive to emphasize strengths, and readers should know when figures originate from a sponsor’s release rather than a complete peer-reviewed evidence package.
Why the Next Diabetes Drug Needs More Than Impressive Numbers
The commercial stakes are high because clinicians already have effective incretin treatments. A new entrant must show something distinctive: greater glucose lowering, different side-effect trade-offs, easier use, more durable results, a better fit for certain patients or credible outcome benefits.
Enicepatide’s September data suggest a potentially competitive glucose-control profile, but that is a hypothesis for later comparative testing. It is not an approved drug or a clinical recommendation.
Roche has already announced two Phase 3 weight-management studies, ENITH-1 and ENITH-2, and plans for a Phase 3 glycemic-control program and cardiovascular outcomes trials beginning in the first half of 2027. Those programs may provide some of the longer-term evidence that this early readout cannot.
This contextual feature belongs beside the newer retatrutide results precisely because it asks a different question. Retatrutide’s October 28 trial offers an active-comparator readout; enicepatide’s September study offers an earlier-stage look at glycemic potential.
Both contribute to a field where receptor biology is expanding rapidly. Neither removes the need for independent scrutiny, longer follow-up and careful matching of treatment to patient.
The real race is not simply to produce the largest number. It is to demonstrate which benefits are meaningful, sustainable and worth the risks.
Sources: Roche, September 22, 2026; ClinicalTrials.gov, NCT06628362; Genentech clinical-trial overview.
